search
Back to results

Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD (CONCERTO)

Primary Purpose

Age-Related Macular Degeneration, Geographic Atrophy

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
smaller incision, new generation implantable miniature telescope (SING-IMT)
Sponsored by
VisionCare, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Age-Related Macular Degeneration focused on measuring cataract, best-corrected distance visual acuity

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be at least 65 years of age at the Pre-operative Visit;
  2. Have ETDRS BCDVA 0.9 to 1.6 logMAR (20/160 to 20/800) at the Pre-operative Visit caused by bilateral central scotomas associated with end-stage AMD;
  3. Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by standard of care fluorescein angiography (FA) prior to the Pre-operative Visit;
  4. Have been monitored by an eye care professional over the 6-month (or longer) period immediately prior to the Pre-operative Visit and have demonstrated no evidence of active choroidal neovascularization (CNV) prior to the Pre-operative Visit as demonstrated by the following:

    1. lack of need of treatment for CNV over the past 6 months, and
    2. lack of active exudative fluid on optical coherence tomography (OCT) over the past 6 months, and
    3. lack of Retinal hemorrhage on exam over a 6-month period or longer
  5. Agree to participate in post-operative visual training

    For the Implanted Eye:

  6. Have evidence of visually significant cataract at the Pre-operative Visit;
  7. Agree to undergo pre-operative training and assessment (1 or more sessions) with low vision specialists (optometrist or occupational therapist) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment

    For the Non-Implanted Eye:

  8. Have adequate peripheral vision at the Pre-operative Visit to allow navigation

Exclusion Criteria:

  1. Have cognitive impairment that would interfere with the ability to understand and provide Informed Consent or prevent proper visual training/rehabilitation with the device;
  2. Have any of the following conditions at the Pre-operative Visit:

    1. Stargardt macular dystrophy;
    2. Diabetic retinopathy;
    3. Untreated retinal tears;
    4. Retinal vascular disease;
    5. Optic nerve disease;
    6. History of retinal detachment;
    7. Intraocular tumor;
    8. Retinitis pigmentosa;
  3. History of steroid-induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP >22 mmHg at the Pre-operative Visit;
  4. Have known allergy to post-operative medications;
  5. History of eye rubbing or an ocular condition that predisposes subject to eye rubbing;
  6. Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit;
  7. Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety;
  8. Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study;
  9. Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit

    For the Implanted Eye:

  10. Have central anterior chamber depth (ACD) <3.0 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit;
  11. Have an Endothelial Cell Density (ECD) below:

    1. 2,000 cells per millimeter, if 65-84 years old;
    2. 1,800 cells per millimeter, if 85 years old or greater (based on the lowest value of the three cell counts performed by technician at investigative site at the Pre-operative Visit)
  12. Have a history of corneal stromal or endothelial dystrophies, including guttata;
  13. Have Myopia > 6.0 D or Hyperopia > 4.0 D by Manifest Refraction at the Pre-operative Visit;
  14. Have an Axial Length (AL) < 21 mm at the Pre-operative Visit;
  15. Have a narrow angle defined as < grade 2 on the Schaffer scale at the Pre-operative Visit;
  16. Ongoing Inflammatory ocular disease at the Pre-operative Visit;
  17. Zonular weakness/instability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit;
  18. Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery;
  19. Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes;

    For the Non-Implanted Eye:

  20. Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.

Sites / Locations

  • Loma Linda UniversityRecruiting
  • California Eye SpecialistsRecruiting
  • Sarasota Retina InstituteRecruiting
  • Tallman Eye AssociatesRecruiting
  • Atlantic Eye Surgery CenterRecruiting
  • Laser Vision Correction CenterRecruiting
  • Asheville Eye AssociatesRecruiting
  • Erie Retinal SurgeryRecruiting
  • Texas Retina CenterRecruiting
  • University Station ClinicRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SING-IMT Implanted

Arm Description

the implanted eye will be the study eye which receives the SING-IMT. Implantation will occur during routine cataract surgery using a proprietary delivery system (loading cartridge and injector), via an approximately 6.5mm incision

Outcomes

Primary Outcome Measures

Primary Effectiveness Outcome
Proportion of study eyes with an improvement of 10 or more ETDRS letters (0.2 logMAR) in either BCDVA or BCNVA at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Primary Safety Outcome
Percent change in endothelial cell density (ECD) from Pre-operative Visit in study eyes at Visit 5 (330 to 420 days post-operatively)

Secondary Outcome Measures

Best-corrected distance visual acuity (BCDVA)
Post-operative BCDVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Best-corrected near visual acuity (BCNVA)
Post-operative BCNVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Anterior Chamber Depth
Anterior Chamber Depth in study eyes, defined as the distance between the corneal endothelium and the front surface of the IMT, at Visit 5 (330 to 420 days post-operatively)
IMT position
IMT tilt and centration in study eyes at Visit 5 (330 to 420 days post-operatively)
Adverse Events
Rates of adverse events from Operative Visit through Visit 5 (330 to 420 days post-operatively)
Posterior Capsule Opacification
Rates of posterior capsule opacification in study eyes at post-operative visit 5 (330 to 420 days post-operatively)

Full Information

First Posted
June 24, 2022
Last Updated
March 28, 2023
Sponsor
VisionCare, Inc.
Collaborators
ORA, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05438732
Brief Title
Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD
Acronym
CONCERTO
Official Title
A Prospective, Multicenter Clinical Study of the Implantable Miniature Telescope, Model SING in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration (AMD)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 16, 2022 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VisionCare, Inc.
Collaborators
ORA, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).
Detailed Description
Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study, including assessment of their best-corrected distance- and near- visual acuity with and without refraction, and also when using an external telescope simulator (ETS) to determine if they are likely to benefit from receiving the IMT. If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery. Following implantation, patients will return for 5 post-operative follow-up visits over a period of approximately 12 months. Additionally, patients will have up to 12 rehabilitation/training visits with a low vision specialist

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age-Related Macular Degeneration, Geographic Atrophy
Keywords
cataract, best-corrected distance visual acuity

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Effectiveness: one-sided asymptotic normal test Safety: one-sided t-test
Masking
None (Open Label)
Masking Description
since the IMT has a unique appearance in the eye, it cannot be masked to the Investigator or to the patient
Allocation
N/A
Enrollment
125 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SING-IMT Implanted
Arm Type
Experimental
Arm Description
the implanted eye will be the study eye which receives the SING-IMT. Implantation will occur during routine cataract surgery using a proprietary delivery system (loading cartridge and injector), via an approximately 6.5mm incision
Intervention Type
Device
Intervention Name(s)
smaller incision, new generation implantable miniature telescope (SING-IMT)
Intervention Description
The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
Primary Outcome Measure Information:
Title
Primary Effectiveness Outcome
Description
Proportion of study eyes with an improvement of 10 or more ETDRS letters (0.2 logMAR) in either BCDVA or BCNVA at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Time Frame
Approximately 12-months post-operatively (330-420 days)
Title
Primary Safety Outcome
Description
Percent change in endothelial cell density (ECD) from Pre-operative Visit in study eyes at Visit 5 (330 to 420 days post-operatively)
Time Frame
Approximately 12-months post-operatively (330-420 days)
Secondary Outcome Measure Information:
Title
Best-corrected distance visual acuity (BCDVA)
Description
Post-operative BCDVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Time Frame
Approximately 12-months post-operatively (330-420 days)
Title
Best-corrected near visual acuity (BCNVA)
Description
Post-operative BCNVA in study eyes at Visit 5 (330 to 420 days post-operatively) compared to Pre-operative Visit
Time Frame
Approximately 12-months post-operatively (330-420 days)
Title
Anterior Chamber Depth
Description
Anterior Chamber Depth in study eyes, defined as the distance between the corneal endothelium and the front surface of the IMT, at Visit 5 (330 to 420 days post-operatively)
Time Frame
Approximately 12-months post-operatively (330-420 days)
Title
IMT position
Description
IMT tilt and centration in study eyes at Visit 5 (330 to 420 days post-operatively)
Time Frame
Approximately 12-months post-operatively (330-420 days)
Title
Adverse Events
Description
Rates of adverse events from Operative Visit through Visit 5 (330 to 420 days post-operatively)
Time Frame
Approximately 12-months post-operatively (330-420 days)
Title
Posterior Capsule Opacification
Description
Rates of posterior capsule opacification in study eyes at post-operative visit 5 (330 to 420 days post-operatively)
Time Frame
Approximately 12-months post-operatively (330-420 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be at least 65 years of age at the Pre-operative Visit; Have ETDRS BCDVA 0.9 to 1.6 logMAR (20/160 to 20/800) at the Pre-operative Visit caused by bilateral central scotomas associated with end-stage AMD; Have bilateral retinal findings of geographic atrophy or disciform scar with foveal involvement, as determined by standard of care fluorescein angiography (FA) prior to the Pre-operative Visit; Have been monitored by an eye care professional over the 6-month (or longer) period immediately prior to the Pre-operative Visit and have demonstrated no evidence of active choroidal neovascularization (CNV) prior to the Pre-operative Visit as demonstrated by the following: lack of need of treatment for CNV over the past 6 months, and lack of active exudative fluid on optical coherence tomography (OCT) over the past 6 months, and lack of Retinal hemorrhage on exam over a 6-month period or longer Agree to participate in post-operative visual training For the Implanted Eye: Have evidence of visually significant cataract at the Pre-operative Visit; Agree to undergo pre-operative training and assessment (1 or more sessions) with low vision specialists (optometrist or occupational therapist) in the use of an external telescope model sufficient for patient assessment and patient must achieve at least a 5-letter ETDRS BCDVA improvement (0.1 logMAR) in the final assessment For the Non-Implanted Eye: Have adequate peripheral vision at the Pre-operative Visit to allow navigation Exclusion Criteria: Have cognitive impairment that would interfere with the ability to understand and provide Informed Consent or prevent proper visual training/rehabilitation with the device; Have any of the following conditions at the Pre-operative Visit: Stargardt macular dystrophy; Diabetic retinopathy; Untreated retinal tears; Retinal vascular disease; Optic nerve disease; History of retinal detachment; Intraocular tumor; Retinitis pigmentosa; History of steroid-induced rise in intraocular pressure (IOP), uncontrolled glaucoma, or IOP >22 mmHg at the Pre-operative Visit; Have known allergy to post-operative medications; History of eye rubbing or an ocular condition that predisposes subject to eye rubbing; Have had prior or expected ophthalmic surgery within 30 days of the Operative Visit; Have any circumstance that, based on the Investigator's judgment, poses a concern for the subject's safety; Any systemic disease or clinical evidence of any condition at the Pre-operative Visit which would make the subject in the opinion of the investigator unsuitable for the study; Concurrent participation or prior participation in any investigative drug or device study within last 30 days prior to Pre-operative Visit For the Implanted Eye: Have central anterior chamber depth (ACD) <3.0 mm from the posterior surface of the cornea (endothelium) to the anterior surface of the crystalline lens at the Pre-operative Visit; Have an Endothelial Cell Density (ECD) below: 2,000 cells per millimeter, if 65-84 years old; 1,800 cells per millimeter, if 85 years old or greater (based on the lowest value of the three cell counts performed by technician at investigative site at the Pre-operative Visit) Have a history of corneal stromal or endothelial dystrophies, including guttata; Have Myopia > 6.0 D or Hyperopia > 4.0 D by Manifest Refraction at the Pre-operative Visit; Have an Axial Length (AL) < 21 mm at the Pre-operative Visit; Have a narrow angle defined as < grade 2 on the Schaffer scale at the Pre-operative Visit; Ongoing Inflammatory ocular disease at the Pre-operative Visit; Zonular weakness/instability of crystalline lens, or pseudoexfoliation at the Pre-operative Visit; Have any condition at the Pre-operative Visit which in the judgement of the Investigator indicates that the haptics cannot be placed within the capsular bag during surgery; Have had previous intraocular or corneal surgery, including any type of surgery for refractive or therapeutic purposes; For the Non-Implanted Eye: Have ophthalmic pathology at the Pre-operative Visit that compromises the patient's peripheral vision based on the Investigator's judgment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rebecca Kammer, OD, PhD
Phone
+1 (714) 728-1575
Email
rkammer@samsaravision.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Adams, PhD, RN
Phone
+1 (858) 344-3250
Email
jadams@oraclinical.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rebecca J Kammer, OD, PhD
Organizational Affiliation
Samsara Vision Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Loma Linda University
City
Loma Linda
State/Province
California
ZIP/Postal Code
92354
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecca Pereyra, BS
Email
rpereyra@llu.edu
First Name & Middle Initial & Last Name & Degree
Norlisha Borntrager, BS
Email
NBorntrager@llu.edu
First Name & Middle Initial & Last Name & Degree
Michael Rauser, MD
Facility Name
California Eye Specialists
City
Pasadena
State/Province
California
ZIP/Postal Code
91107
Country
United States
Individual Site Status
Recruiting
Facility Name
Sarasota Retina Institute
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34239
Country
United States
Individual Site Status
Recruiting
Facility Name
Tallman Eye Associates
City
Lawrence
State/Province
Massachusetts
ZIP/Postal Code
01843
Country
United States
Individual Site Status
Recruiting
Facility Name
Atlantic Eye Surgery Center
City
Eatontown
State/Province
New Jersey
ZIP/Postal Code
07724
Country
United States
Individual Site Status
Recruiting
Facility Name
Laser Vision Correction Center
City
Whippany
State/Province
New Jersey
ZIP/Postal Code
07981
Country
United States
Individual Site Status
Recruiting
Facility Name
Asheville Eye Associates
City
Asheville
State/Province
North Carolina
ZIP/Postal Code
28803
Country
United States
Individual Site Status
Recruiting
Facility Name
Erie Retinal Surgery
City
Erie
State/Province
Pennsylvania
ZIP/Postal Code
16507
Country
United States
Individual Site Status
Recruiting
Facility Name
Texas Retina Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
University Station Clinic
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD

We'll reach out to this number within 24 hrs